THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.6]-C153 ID: TIP-MED-000423

Nadifloxacin

Active Ingredient / Scientific Identity: Nadifloxacin • Class: Topical Corticosteroids (Grouped by Potency: Super-Potent Clobetasol, Potent Mometasone/Betamethasone, Mild Hydrocortisone), Topical Imidazole/Allylamine Antifungals (Luliconazole, Clotrimazole, Sertaconazole, Terbinafine, Ketoconazole), Topical Antibacterials (Mupirocin, Fusidic Acid), and Ectoparasiticides (Permethrin 5%)

⚖️ Compare Profile
Generic / Entity NameNadifloxacin ([12.6]-C153)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTopical Corticosteroids (Grouped by Potency: Super-Potent Clobetasol, Potent Mometasone/Be
Available Dosage FormsCreams (water-miscible base for weeping/acute/intertriginous lesions), Ointments (occlusive greasy base for dr
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal & Hepatic: No adjustment required for standard localised topical use. Caution: Applying >50 g/week of super-potent Clob
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Nadifloxacin (TIP-MED-000423, Reference Code [12.6]-C153) is classified under Dermatological & Topical Antiseptic Preparations (Ch 12) as a Topical Corticosteroids (Grouped by Potency: Super-Potent Clobetasol, Potent Mometasone/Betamethasone, Mild Hydrocortisone), Topical Imidazole/Allylamine Antifungals (Luliconazole, Clotrimazole, Sertaconazole, Terbinafine, Ketoconazole), Topical Antibacterials (Mupirocin, Fusidic Acid), and Ectoparasiticides (Permethrin 5%). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [12.6] (Fusidic Acid, Nadifloxacin & Ketoconazole Topical Preparations (Dermatological Anti-Infectives)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.6], p. 157): • Topical Corticosteroids: Super-Potent (Class I): Clobetasol Propionate 0.05% (Tenovate, Lobate, Topinate); Halobetasol 0.05% (Halovate). Potent (Class II–III): Mometasone Furoate 0.1% (Momate, Elocon); Betamethasone Valerate/Dipropionate 0.05%–0.1% (Betnovate, Diprovate); Fluticasone 0.05% (Flutivate). Low-Potency (Class VI–VII—Face/Intertriginous/Paediatric): Desonide 0.05% (Desowen); Hydrocortisone Acetate 1% (Wycort). • Pure Topical Antifungals (Tinea/Candidiasis): Luliconazole 1% (Lulifin, Lulican—OD); Clotrimazole 1% (Candid Cream/Dusting Powder); Amorolfine/Sertaconazole/Eberconazole/Terbinafine 1% (Sebifin, Tyza); Ketoconazole 2% Shampoo (Nizral, Scalpe). • Topical Antibacterials (Impetigo/Folliculitis): Mupirocin 2% (T-Bact [GSK], Bactroban); Fusidic Acid 2% (Fudic, Fusiwal). — Strengths & Dosage Forms: Creams (water-miscible base for weeping/acute/intertriginous lesions), Ointments (occlusive greasy base for dry, thick, lichenified plaques on palms/soles/extensors), Lotions/Solutions (for hairy scalp)
Co-indexed constituent under primary monograph [12.6] (Fusidic Acid, Nadifloxacin & Ketoconazole Topical Preparations (Dermatological Anti-Infectives)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.6], p. 157): • Topical Corticosteroids: Super-Potent (Class I): Clobetasol Propionate 0.05% (Tenovate, Lobate, Topinate); Halobetasol 0.05% (Halovate). Potent (Class II–III): Mometasone Furoate 0.1% (Momate, Elocon); Betamethasone Valerate/Dipropionate 0.05%–0.1% (Betnovate, Diprovate); Fluticasone 0.05% (Flutivate). Low-Potency (Class VI–VII—Face/Intertriginous/Paediatric): Desonide 0.05% (Desowen); Hydrocortisone Acetate 1% (Wycort). • Pure Topical Antifungals (Tinea/Candidiasis): Luliconazole 1% (Lulifin, Lulican—OD); Clotrimazole 1% (Candid Cream/Dusting Powder); Amorolfine/Sertaconazole/Eberconazole/Terbinafine 1% (Sebifin, Tyza); Ketoconazole 2% Shampoo (Nizral, Scalpe). • Topical Antibacterials (Impetigo/Folliculitis): Mupirocin 2% (T-Bact [GSK], Bactroban); Fusidic Acid 2% (Fudic, Fusiwal). — Strengths & Dosage Forms: Creams (water-miscible base for weeping/acute/intertriginous lesions), Ointments (occlusive greasy base for dry, thick, lichenified plaques on palms/soles/extensors), Lotions/Solutions (for hairy scalp)
Dosage Forms & Available Strengths:
Creams (water-miscible base for weeping/acute/intertriginous lesions), Ointments (occlusive greasy base for dry, thick, lichenified plaques on palms/soles/extensors), Lotions/Solutions (for hairy scalp)
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Topical Corticosteroids (Grouped by Potency: Super-Potent Clobetasol, Potent Mometasone/Betamethasone, Mild Hydrocortisone), Topical Imidazole/Allylamine Antifungals (Luliconazole, Clotrimazole, Sertaconazole, Terbinafine, Ketoconazole), Topical Antibacterials (Mupirocin, Fusidic Acid), and Ectoparasiticides (Permethrin 5%) acting on target receptor/enzyme pathways in Dermatological & Topical Antiseptic Preparations (Ch 12): clinical efficacy is mediated via Topical Corticosteroids (Grouped by Potency: Super-Potent Clobetasol, Potent Mometasone/Betamethasone, Mild Hydrocortisone), Topical Imidazole/Allylamine Antifungals (Luliconazole, Clotrimazole, Sertaconazole, Terbinafine, Ketoconazole), Topical Antibacterials (Mupirocin, Fusidic Acid), and Ectoparasiticides (Permethrin 5%) for • Topical Corticosteroids: Eczema / atopic dermatitis, contact dermatitis, plaque psoriasis, lichen planus, seborrhoeic dermatitis. • Pure Topical Antifungals: Dermatophytosis (Tinea corporis, Tinea cruris [dhobi itch], Tinea pedis), cutaneous candidiasis, pityriasis versicolor. • Topical Antibacterials: Impetigo, folliculitis, infected eczema/wounds, nasal MRSA decolonisation (Mupirocin)..

4. Therapeutic Indications & Evidence-Supported Uses

  • • Topical Corticosteroids: Eczema / atopic dermatitis, contact dermatitis, plaque psoriasis, lichen planus, seborrhoeic dermatitis
  • • Pure Topical Antifungals: Dermatophytosis (Tinea corporis, Tinea cruris [dhobi itch], Tinea pedis), cutaneous candidiasis, pityriasis versicolor
  • • Topical Antibacterials: Impetigo, folliculitis, infected eczema/wounds, nasal MRSA decolonisation (Mupirocin)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Quantified by the Finger-Tip Unit (FTU)! 1 FTU (the ribbon of cream/ointment squeezed from a standard 5 mm nozzle along the adult index fingertip from the tip to the first distal crease) equals 0.5 grams and covers an area equal to 2 adult flat palms (with fingers together). • Topical Steroids: Apply a thin film once or twice daily for 1 to 2 weeks (up to 4 weeks on thick palms/soles). • Pure Antifungals: Apply to the lesion AND a 2 cm normal-looking border around the rash once daily (Luliconazole/Terbinafine) or twice daily (Clotrimazole/Sertaconazole) for at least 2 weeks AFTER the rash completely disappears (total 4 to 6 weeks)!

Administration & Meal Timing: External topical application only after washing and gently drying affected skin; wash hands before and after application (unless treating hands). Separate steroid cream and bland emollient by 20–30 minutes. | Once or twice daily after bathing and drying the skin thoroughly.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [12.6].
Metabolism & Biotransformation:
Renal & Hepatic: No adjustment required for standard localised topical use. Caution: Applying >50 g/week of super-potent Clobetasol 0.05% over extensive denuded skin or under occlusion causes percutaneous systemic absorption, HPA-axis adrenal suppression, and iatrogenic Cushing's syndrome.
Elimination & Renal Adjustment:
Renal & Hepatic: No adjustment required for standard localised topical use. Caution: Applying >50 g/week of super-potent Clobetasol 0.05% over extensive denuded skin or under occlusion causes percutaneous systemic absorption, HPA-axis adrenal suppression, and iatrogenic Cushing's syndrome.
Hepatic Impairment Considerations:
Renal & Hepatic: No adjustment required for standard localised topical use. Caution: Applying >50 g/week of super-potent Clobetasol 0.05% over extensive denuded skin or under occlusion causes percutaneous systemic absorption, HPA-axis adrenal suppression, and iatrogenic Cushing's syndrome.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. THE EPIDEMIC INDIAN 'RINGWORM STEROID-COMBINATION' DISASTER (STRICT PHARMACIST BAN!): Across India, irrational fixed-dose triple/quadruple skin tubes combining a Super-Potent Steroid (Clobetasol) + Antifungal + Antibacterial (such as Panderm+, Quadriderm, Fourderm, Castor NF, Lobate-GM, Betnovate-C/N) are widely abused for fungal ringworm (Tinea cruris/corporis) and as fairness creams! Applying Clobetasol or Betnovate to a fungal infection suppresses local skin immunity—causing initial 2-day itch relief followed by explosive, treatment-resistant fungal spread ('Tinea Incognito'), irreversible purple skin striae (stretch marks), skin atrophy, telangiectasia, steroid rosacea, and HPA-axis Cushing's syndrome! NEVER dispense a steroid-containing cream for fungal ringworm, groin itch, acne, or facial fairness! 2. Never apply potent steroids (Clobetasol, Betamethasone) to the face, eyelids (causes glaucoma/cataracts!), axilla, or groin/genitalia!

Key Clinical Precautions: Renal & Hepatic: No adjustment required for standard localised topical use. Caution: Applying >50 g/week of super-potent Clobetasol 0.05% over extensive denuded skin or under occlusion causes percutaneous systemic absorption, HPA-axis adrenal suppression, and iatrogenic Cushing's syndrome.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Local transient stinging or burning; with prolonged/potent steroid misuse: skin thinning (epidermal atrophy), striae distensae, hypopigmentation, hypertrichosis, acneiform eruptions, perioral dermatitis.
  • Systemic hypothalamic-pituitary-adrenal (HPA) axis suppression and iatrogenic Cushing's syndrome (when >50 g/week of Clobetasol 0.05% is applied over large body surfaces or under occlusion), glaucoma/cataracts (from periocular steroid use), recalcitrant steroid-modified dermatophytosis.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Minimal systemic drug interactions unless large-surface super-potent steroids are absorbed

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.6].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: 1. Enforce the '2-cm Margin & 2-Week Extra' Rule for Fungal Creams (Lulifin/Candid): Tell patients with groin/body ringworm to apply pure antifungal cream 2 cm beyond the red border and keep applying for 2 full weeks after the skin looks clear, while boiling/sun-drying cotton innerwear and avoiding tight damp clothes. 2. Demonstrate the Finger-Tip Unit (FTU) for steroid creams so patients apply a thin sheen rather than rubbing in half a tube. 3. If both a steroid cream and an emollient/moisturiser (liquid paraffin/white soft paraffin) are prescribed for eczema, wait 20–30 minutes between applying the steroid and the moisturiser. 4. For Permethrin 5% Cream (Perlice / Scabper for Scabies): Apply from the chin/jawline down to the soles of the feet (including webs between fingers/toes, wrists, navel, and groin), leave on overnight for 8 to 14 hours, wash off in the morning, treat all close family members simultaneously, wash bedsheets in hot water, and repeat a 2nd application exactly 7 days later! Explain that mild 'post-scabietic itching' can persist for 1–2 weeks after the mites are dead and does not mean treatment failed.
    • Meal & Clock Timing Instruction: External topical application only after washing and gently drying affected skin; wash hands before and after application (unless treating hands). Separate steroid cream and bland emollient by 20–30 minutes. (Once or twice daily after bathing and drying the skin thoroughly.)
    • Missed Dose Protocol: Apply as soon as remembered; do not apply double thickness.
    • Geriatric Dispensing Pearl: Elderly CGHS patients have thin, fragile, xerotic (dry) senile skin with an impaired epidermal barrier—applying potent steroids (Tenovate/Betnovate) rapidly causes senile purpura, skin tearing, and ulceration. Encourage generous daily application of bland emollients (white soft paraffin + liquid paraffin) immediately after bathing while skin is damp.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Creams (water-miscible base for weeping/acute/intertriginous lesions), Ointments (occlusive greasy base for dry, thick, lichenified plaques on palms/soles/extensors), Lotions/Solutions (for hairy scalp)

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.